NCT04883918View on ClinicalTrials.gov

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
Acute-graft-versus-host Disease
Interventions
BIOLOGICAL

ASC930

4 intravenous doses of ASC930

Sponsors

Lead Sponsor

ASC Therapeutics
All Listed Sponsors
lead

ASC Therapeutics

INDUSTRY